The DRUP (Drug Rediscovery Protocol) trial pioneers a paradigm shift by utilizing comprehensive genomic profiling to match patients with targeted therapies originally approved for other cancer types but potentially effective due to shared molecular alterations. This approach addresses the pervasive challenge of precision oncology: the scarcity of approved treatments tailored to the diverse mutational landscapes present in cancers beyond their initial labeled indications. By transcending conventional tumor-type boundaries and focusing on molecular drivers, DRUP facilitates access to personalized interventions that might otherwise remain inaccessible.

Central to the trial’s success is its sophisticated whole-genome sequencing analysis, which elucidates intricate tumor DNA alterations such as mutations, deletions, amplifications, and structural rearrangements. These genomic aberrations, often cryptic to traditional diagnostic modalities, serve as predictive biomarkers for drug sensitivity. Harnessing this information enables oncologists to identify actionable targets within a heterogeneous patient population, thereby expanding therapeutic possibilities and refining treatment decision-making. This strategy epitomizes a precision medicine ethos that seeks not merely to combat cancer but to contiguously tailor interventions to individual tumor biology.

Over the decade-spanning DRUP trial, approximately one-third of participants demonstrated either measurable tumor regression or maintained disease stability for a minimum of four months, a clinically meaningful benchmark in the context of refractory cancers. The median overall survival observed was eight months, with a quarter of patients experiencing significant adverse effects. Importantly, the spectrum of responses revealed a subset of 67 exceptional responders who exhibited complete tumor eradication or sustained progression-free survival exceeding two years. These durable responses underscore the profound impact that targeted off-label drug application can achieve within an appropriate genomic context.

The implications of these findings extend beyond individual patient benefit; they advocate for a systematic, trial-based approach to off-label cancer drug prescription. Principal investigator Emile Voest emphasizes that unregulated off-label use outside clinical trials poses substantial risks, including unpredictable toxicity, financial burdens, and disparities in access to emerging treatments. By embedding off-label therapies within validated clinical protocols, the oncology community can rigorously monitor safety profiles, efficacy outcomes, and real-world applicability, fostering responsible innovation while safeguarding patients.

A particularly noteworthy success story from the DRUP initiative pertains to the treatment of microsatellite instability (MSI) tumors. An expansion cohort within the trial generated compelling evidence supporting national reimbursement approval for an off-label therapy targeting MSI-high cancers. This milestone illustrates how evidence amassed through genomics-driven trials can catalyze drug label expansions and broaden public healthcare coverage, ultimately streamlining access to life-saving therapies for genetically defined patient subsets.

The DRUP trial methodology has galvanized the establishment of a pan-European consortium implementing DRUP-like protocols. This network leverages the power of collaborative data sharing and harmonized molecular diagnostics, creating an unprecedented repository of evidence especially valuable for patients with rare cancers. Given the limited availability of conventional clinical trial opportunities for uncommon malignancies, such cross-institutional partnerships empower clinicians to extend precision treatment paradigms and generate robust efficacy data to inform future regulatory decisions.

Notably, prior analyses of DRUP data have revealed that comprehensive genomic testing yields comparable clinical benefit for patients with rare cancers as it does for those with common tumors. This revelation challenges existing oncological practices that often deprioritize extensive molecular profiling in rare malignancies due to perceived cost-effectiveness concerns. Instead, these findings advocate for equitable implementation of high-resolution genomic diagnostics across all cancer subtypes, promoting inclusivity in precision oncology.

The DRUP trial outcomes also elucidate the importance of molecular subgroup stratification in predicting therapeutic response. By dissecting heterogeneity at the genomic level, researchers can identify patient cohorts most likely to derive benefit from specific targeted agents, thereby enhancing the therapeutic index and optimizing resource utilization. This stratified medicine approach marries the patient’s unique tumor biology with the mechanistic underpinnings of available drugs, maximizing the probability of favorable outcomes while minimizing unnecessary exposure.

Emile Voest and collaborators underscore the imperative that off-label targeted cancer therapy must be embedded within prospective clinical trials, ensuring rigorous evaluation and evidence generation. This stance responds to the expanding arsenal of anticancer agents and the growing demand for personalized approaches that transcend traditional labeling constraints. Ultimately, the DRUP trial illuminates a path forward where genomic insights guide dynamic, evidence-based off-label drug use, thereby expanding the therapeutic horizon in oncology.

The extensive financial support from organizations including KWF Dutch Cancer Society and Stelvio for Life has been instrumental in conducting this ambitious study. The multi-institutional collaboration deployed state-of-the-art sequencing and analytics, underscoring the synergy between cutting-edge technology and clinical innovation. As the oncology landscape evolves, initiatives such as DRUP exemplify the integration of translational research into clinical practice, fostering adaptive treatment strategies responsive to tumor evolution and molecular complexity.

In summary, the DRUP study provides compelling evidence that genomics-guided off-label targeted therapies can confer meaningful benefits to patients with advanced and hard-to-treat cancers. By merging comprehensive molecular characterization with adaptive clinical trial design, the study establishes a versatile framework to unlock the latent potential of existing cancer drugs. The resultant paradigm offers renewed hope for patients facing limited options and highlights the necessity of harmonized efforts to systematically evaluate and implement precision oncology solutions on a global scale.

Subject of Research: People

Article Title: Prospective evaluation of genomics-guided off-label treatment

News Publication Date: 15-Apr-2026

Web References:

• DRUP trial: https://drupstudy.nl/
• Article DOI: http://dx.doi.org/10.1038/s41586-026-10405-x

References:

• Expansion cohort evidence for MSI treatment: https://pubmed.ncbi.nlm.nih.gov/39024037/
• DRUP-like protocols discussion: https://pubmed.ncbi.nlm.nih.gov/38779910/

Image Credits: ©Netherlands Cancer Institute

Keywords: Cancer treatments, Cancer genomics, Off-label cancer therapy, Precision oncology, Whole genome sequencing, Targeted therapy, Molecular profiling, Rare cancers, Clinical trials, Drug repurposing

Targefrin represents a groundbreaking approach in targeting EphA2, or ephrin type-A receptor 2, a receptor tyrosine kinase that is markedly overexpressed in a variety of cancers including pancreatic, prostate, lung, breast, ovarian, and colorectal malignancies. EphA2’s aberrant expression facilitates cancer metastasis by promoting cancer cell migration from the primary tumor and enabling colonization of distant tissues. The ability of Targefrin to selectively degrade EphA2 offers a paradigm shift in controlling tumor progression and metastasis.

The molecule known as Targefrin was originally discovered in the laboratory of Maurizio Pellecchia, a renowned professor at the UCR School of Medicine and one of Armida Labs’ co-founders. Pellecchia’s pioneering work led to the conceptualization of Targefrin as a dimeric peptide mimetic designed to engage EphA2 in a unique mechanism of action. The IND-enabling studies will be overseen by Carlo Baggio, Armida Labs’ co-founder and chief technology officer, who serves as principal investigator for the grant.

Baggio highlighted that the laboratory’s multi-year focus on EphA2 has culminated in Targefrin’s evolution. “EphA2 is a key driver of pancreatic cancer aggressiveness,” he noted, “and elevated EphA2 expression is associated with dismal patient prognosis. Targefrin’s mechanism — effectively degrading EphA2 — has the potential to convert aggressive tumors into less invasive phenotypes.” The successful Phase I SBIR award of $600,000 laid the foundation for this current expanded research endeavor.

Delving into the biochemistry of Targefrin reveals a sophisticated molecular design inspired by nature’s own regulatory systems. The molecule is a dimeric peptide mimetic, structurally engineered to emulate ephrins—natural ligands of the EphA2 receptor. Through dimerization, Targefrin induces receptor clustering, a biological process that triggers internalization and degradation of EphA2 from the cancer cell surface. This targeted receptor downregulation disrupts the pro-oncogenic signaling cascade that EphA2 mediates in its ligand-independent, overexpressed state.

EphA2’s dualistic nature in cancer biology is critical to understanding Targefrin’s therapeutic rationale. Under normal physiological conditions, EphA2 interactions with ephrin ligands suppress tumorigenesis by inhibiting cell migration and proliferation. However, in many solid tumors, including pancreatic and prostate cancers, EphA2 is upregulated independently of its ligands, converting it into a pro-metastatic oncoprotein. This ligand-independent EphA2 promotes cellular motility, invasion, and establishment of metastatic niches, representing a formidable obstacle in cancer therapy. Targefrin’s ability to restore balance by mimicking ligand binding and triggering receptor degradation directly counteracts this pathological state.

The development pipeline for Targefrin involved an iterative chemical design process, meticulously refining the molecule to optimize its affinity and selectivity for EphA2. Each chemical modification sought to enhance pharmacodynamic properties while maintaining specificity, a critical factor for minimizing off-target effects and improving therapeutic indices. This rational drug design process exemplifies the intersection of medicinal chemistry and molecular biology driving next-generation cancer therapeutics.

Looking forward, Armida Labs is committed to advancing Targefrin through rigorous IND-enabling studies using the current SBIR funding. The primary focus is pancreatic cancer, one of the most lethal and treatment-resistant malignancies worldwide, underscoring the urgent need for novel therapeutic agents. Beyond pancreatic cancer, the scope of Targefrin’s application may extend to a wide range of EphA2-driven tumors, potentiating broad clinical impact.

The research team is optimistic about the translational potential of Targefrin and the implications for targeted therapy in metastatic disease. Pellecchia expressed enthusiasm: “Coming from an academic laboratory setting to startup verification embodies the spirit of translational medicine. With this funding, we are poised to move this innovative molecule closer to clinical reality.” He emphasized that additional support through fundraising will be vital to propel the molecule into early phase clinical trials.

Technical insights into Targefrin’s mode-of-action illustrate its distinction from traditional small-molecule inhibitors or monoclonal antibodies targeting receptor tyrosine kinases. Instead of competitive inhibition, Targefrin leverages induced receptor dimerization to hijack the natural receptor downregulation pathway, effectively removing the pro-tumorigenic receptor from the cancer cell architecture. This biological elegance represents an advanced modality in therapeutic design, addressing the unmet challenge of targeting overexpressed receptors in a ligand-deficient microenvironment.

The advancement of Targefrin is emblematic of a broader trend in oncology drug development focusing on protein degradation technologies, including proteolysis targeting chimeras (PROTACs) and similar modalities. Targefrin contributes to this evolving landscape by utilizing receptor dimerization-induced degradation, a less explored but highly promising avenue. If successful, this strategy may inspire novel approaches for other receptor-driven cancers.

Beyond the molecular frontiers, the initiative by Armida Labs underscores the critical role of academic-industry partnerships and government-funded innovation programs in accelerating cancer drug discovery. The SBIR grants exemplify how carefully structured funding mechanisms can bridge early-stage scientific discoveries with translational development, fostering the pipeline for novel therapeutics tailored to pressing clinical needs.

As Armida Labs moves forward, the oncology community will keenly watch the outcomes of these preclinical studies. The potential to transform metastatic cancer treatment could herald a new era where therapeutics not only inhibit tumor growth but also dismantle the cellular mechanisms facilitating metastasis, improving survival and quality of life for countless patients worldwide.

Subject of Research: Anti-metastatic therapy targeting EphA2 receptor in cancer using a dimeric peptide mimetic.
Article Title: Not provided.
News Publication Date: Not provided.
Web References:

• Armida Labs: http://armida-labs.com/
• UCR School of Medicine: https://profiles.ucr.edu/app/home/profile/maurizio
• Center for Molecular and Translational Medicine: https://molmed.ucr.edu/
• Armida Labs Team: https://www.armidalabs.com/armida-labs-team/carlo-baggio-ph-d
• UCR homepage: http://www.ucr.edu/
  Image Credits: Armida Labs, Inc.
  Keywords: Targefrin, EphA2, anti-metastatic agent, pancreatic cancer, receptor degradation, peptide mimetic, cancer metastasis, preclinical studies, SBIR grant, National Cancer Institute, molecular targeted therapy, peptide dimerization.